EntryPoint Capital LLC acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,731 shares of the company’s stock, valued at approximately $262,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. PDT Partners LLC purchased a new stake in shares of Ginkgo Bioworks during the 3rd quarter valued at about $1,199,000. Erste Asset Management GmbH purchased a new stake in shares of Ginkgo Bioworks during the third quarter valued at approximately $4,075,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Ginkgo Bioworks during the third quarter worth $2,282,000. BNP Paribas Financial Markets purchased a new position in shares of Ginkgo Bioworks in the third quarter valued at $1,287,000. Finally, Verition Fund Management LLC acquired a new stake in Ginkgo Bioworks during the 3rd quarter valued at $792,000. Institutional investors and hedge funds own 78.63% of the company’s stock.
Ginkgo Bioworks Price Performance
Shares of DNA stock opened at $6.16 on Friday. The company’s fifty day moving average price is $10.36 and its two-hundred day moving average price is $9.22. The firm has a market capitalization of $357.26 million, a P/E ratio of -0.47 and a beta of 1.23. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $47.60.
Ginkgo Bioworks Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
- Five stocks we like better than Ginkgo Bioworks
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- How to Calculate Retirement Income: MarketBeat’s Calculator
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
